Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy

Abstract

Endometrial cancer is primarily treated with surgery. Adjuvant treatment strategies for endometrial cancer, such as external beam pelvic radiotherapy, vaginal brachytherapy, chemotherapy, and combined chemotherapy and radiotherapy, have been studied in several randomized trials. Adjuvant treatment is currently based on the presence of clinico-pathological risk factors. Low-risk disease is adequately managed with surgery alone. In high-intermediate risk endometrial cancer, adjuvant vaginal brachytherapy is recommended to maximize local control, with only mild side effects and without impact on quality of life. For high-risk endometrial cancer, recent large randomized trials support the use of pelvic radiotherapy, especially in stage I–II endometrial cancer with risk factors. For women with serous cancers and those with stage III disease, chemoradiation increased both recurrence-free and overall survival, while GOG-258 showed similar recurrence-free survival compared with six cycles of chemotherapy alone, but with better pelvic and para-aortic nodal control with combined chemotherapy and radiotherapy. Recent molecular studies, most notably the work from The Cancer Genome Atlas (TCGA) project, have shown that four endometrial cancer molecular classes can be distinguished; POLE ultra-mutated, microsatellite instable hypermutated, copy-number-low, and copy-number-high. Subsequent studies, using surrogate markers to identify groups analogous to TCGA sub-classes, showed that all four endometrial cancer sub-types are found across all stages, histological types, and grades. Moreover, the molecular sub-groups have proved to have a stronger prognostic impact than histo-pathological tumor characteristics. This introduces an new era of molecular classification based diagnostics and treatment approaches. Integration of the molecular factors and new therapeutic targets will lead to molecular-integrated adjuvant treatment including targeted treatments, which are the rationale of new and ongoing trials. This review presents an overview of current adjuvant treatment strategies in endometrial cancer, highlights the development and evaluation of a molecular-integrated risk profile, and briefly discusses ongoing developments in targeted treatment.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 78

1. 1.

   Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer 2016;26:2–30.

   Not in our library10.1097/igc.0000000000000609

2. 2.

   Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 2017;18:384–92.

   Not in our library10.1016/s1470-2045(17)30068-2

3. 3.

   Bosse T, Peters EEM, Creutzberg CL, et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--a pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 2015;51:1742–50.

   Not in our library10.1016/j.ejca.2015.05.015

4. 4.

   Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744–51.

   Not in our library10.1016/j.ygyno.2003.11.048

5. 5.

   Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 2000;355:1404–11.

   Not in our library10.1016/s0140-6736(00)02139-5

6. 6.

   ASTEC/EN.5 Study Group, Blake P, Swart AM, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009;373:137–46.

   Not in our library10.1016/s0140-6736(08)61767-5

7. 7.

   Sorbe B, Horvath G, Andersson H, et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study. Int J Radiat Oncol Biol Phys 2012;82:1249–55.

   Not in our library10.1016/j.ijrobp.2011.04.014

8. 8.

   Nout RA, Smit VTHBM, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375:816–23.

   Not in our library10.1016/s0140-6736(09)62163-2

9. 9.

   Creutzberg CL, van Putten WLJ, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 2003;89:201–9.

   Not in our library10.1016/s0090-8258(03)00126-4

10. 10.

    Creutzberg CL, Nout RA, Lybeert MLM, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e631–8.

    Not in our library10.1016/j.ijrobp.2011.04.013

11. 11.

    Scholten AN, van Putten WLJ, Beerman H, et al. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63:834–8.

    Not in our library10.1016/j.ijrobp.2005.03.007

12. 12.

    de Boer SM, Nout RA, Jürgenliemk-Schulz IM, et al. Long-term impact of endometrial cancer diagnosis and treatment on health-related quality of life and cancer survivorship: results from the randomized PORTEC-2 trial. Int J Radiat Oncol Biol Phys 2015;93:797–809.

    Not in our library10.1016/j.ijrobp.2015.08.023

13. 13.

    Creasman WT, Kohler MF, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 2004;95:593–6.

    Not in our library10.1016/j.ygyno.2004.08.019

14. 14.

    Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2006;24:36–44.

    Not in our library10.1200/jco.2004.00.7617

15. 15.
    Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial · 2006

    No notice
16. 16.

    Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008;108:226–33.

    Not in our library10.1016/j.ygyno.2007.09.029

17. 17.

    Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer 2010;46:2422–31.

    Not in our library10.1016/j.ejca.2010.06.002

18. 18.

    Randall ME, Filiaci V, McMeekin DS, et al. Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-Intermediate and high-risk early stage endometrial cancer. J Clin Oncol 2019;37:1810–8.

    Not in our library10.1200/jco.18.01575

19. 19.

    Greven K, Winter K, Underhill K, et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006;103:155–9.

    Not in our library10.1016/j.ygyno.2006.02.007

20. 20.
    Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial · 2019

    Corrected
21. 21.

    Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med 2019;380:2317–26.

    Not in our library10.1056/nejmoa1813181

22. 22.
    Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial · 2018

    Corrected
23. 23.

    de Boer SM, Powell ME, Mileshkin L, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2016;17:1114–26.

    Not in our library10.1016/s1470-2045(16)30120-6

24. 24.

    Mundt AJ, McBride R, Rotmensch J, et al. Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:1145–53.

    Not in our library10.1016/s0360-3016(01)01566-8

25. 25.

    Ho JC, Allen PK, Jhingran A, et al. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol 2015;139:40–6.

    Not in our library10.1016/j.ygyno.2015.07.096

26. 26.

    Shirvani SM, Klopp AH, Likhacheva A, et al. Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer. Pract Radiat Oncol 2013;3:e21–8.

    Not in our library10.1016/j.prro.2012.03.013

27. 27.

    Townamchai K, Poorvu PD, Damato AL, et al. Radiation dose escalation using intensity modulated radiation therapy for gross unresected node-positive endometrial cancer. Pract Radiat Oncol 2014;4:90–8.

    Not in our library10.1016/j.prro.2013.07.002

28. 28.

    Klopp AH, Yeung AR, Deshmukh S, et al. Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203. J Clin Oncol 2018;36:2538–44.

    Not in our library10.1200/jco.2017.77.4273

29. 29.

    Yeung AR, Pugh SL, Klopp AH, et al. Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: a report from the NRG Oncology RTOG 1203 study. J Clin Oncol 2020;38:1685–92.

    Not in our library10.1200/jco.19.02381

30. 30.

    Secord AA, Havrilesky LJ, O'Malley DM, et al. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol 2009;114:442–7.

    Not in our library10.1016/j.ygyno.2009.06.005

31. 31.

    Barney BM, Petersen IA, Mariani A, et al. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. Int J Radiat Oncol Biol Phys 2013;85:109–15.

    Not in our library10.1016/j.ijrobp.2012.03.011

32. 32.

    Nasioudis D, Roy AG, Ko EM, et al. Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium. Int J Gynecol Cancer 2020;30:1089–94.

    Not in our library10.1136/ijgc-2020-001379

33. 33.

    Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 2013;37:874–81.

    Not in our library10.1097/pas.0b013e31827f576a

34. 34.

    Khalifa MA, Dodge J, Covens A, et al. Slide review in gynecologic oncology ensures completeness of reporting and diagnostic accuracy. Gynecol Oncol 2003;90:425–30.

    Not in our library10.1016/s0090-8258(03)00323-8

35. 35.

    de Boer SM, Wortman BG, Bosse T, et al. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Ann Oncol 2018;29:424–30.

    Not in our library10.1093/annonc/mdx753

36. 36.

    Scholten AN, Creutzberg CL, Noordijk EM, et al. Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system. Int J Radiat Oncol Biol Phys 2002;52:1067–74.

    Not in our library10.1016/s0360-3016(01)02710-9

37. 37.

    Peters EEM, Bartosch C, McCluggage WG, et al. Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer. Histopathology 2019;75:128–36.

    Not in our library10.1111/his.13871

38. 38.

    Stålberg K, Bjurberg M, Borgfeldt C, et al. Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) study. Acta Oncol 2019;58:1628–33.

    Not in our library10.1080/0284186x.2019.1643036

39. 39.

    Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67–73.

    Not in our library10.1038/nature12113

40. 40.
    Interpretation of somatic POLE mutations in endometrial carcinoma · 2020

    No notice
41. 41.
    Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer · 2014

    No notice
42. 42.

    van Gool IC, Eggink FA, Freeman-Mills L, et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res 2015;21:3347–55.

    Not in our library10.1158/1078-0432.ccr-15-0057

43. 43.

    Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 2015;1:1319–23.

    Not in our library10.1001/jamaoncol.2015.2151

44. 44.

    Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res 2016;22:4215–24.

    Not in our library10.1158/1078-0432.ccr-15-2878

45. 45.
    Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy · 2020

    No notice
46. 46.

    Horeweg N, de Bruyn M, Nout R, et al. Integrated image-based immune and molecular profiling refines prognostication in early-stage endometrial cancer. Cancer Immunol Res. In Press 2020.

    Not in our library10.1158/2326-6066.cir-20-0149

47. 47.

    Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015;113:299–310.

    Not in our library10.1038/bjc.2015.190

48. 48.

    Leenen CHM, van Lier MGF, van Doorn HC, et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years. Gynecol Oncol 2012;125:414–20.

    Not in our library10.1016/j.ygyno.2012.01.049

49. 49.

    Brett MA, Atenafu EG, Singh N, et al. Equivalent survival of p53 mutated endometrial endometrioid carcinoma grade 3 and endometrial serous carcinoma. Int J Gynecol Pathol 2020.. [Epub ahead of print: 06 Apr 2020].

    Not in our library10.1097/pgp.0000000000000674

50. 50.

    de Jonge MM, Auguste A, van Wijk LM, et al. Frequent homologous recombination deficiency in high-grade endometrial carcinomas. Clin Cancer Res 2019;25:1087–97.

    Not in our library10.1158/1078-0432.ccr-18-1443

51. 51.

    Kurnit KC, Kim GN, Fellman BM, et al. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol 2017;30:1032–41.

    Not in our library10.1038/modpathol.2017.15

52. 52.
    Incorporation of molecular characteristics into endometrial cancer management · 2019

    No notice
53. 53.
    Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas · 2020

    No notice
54. 54.

    Depreeuw J, Stelloo E, Osse EM, et al. Amplification of 1q32.1 refines the molecular classification of endometrial carcinoma. Clin Cancer Res 2017;23:7232–41.

    Not in our library10.1158/1078-0432.ccr-17-0566

55. 55.

    Bosse T, Nout RA, Stelloo E, et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. Eur J Cancer 2014;50:2602–10.

    Not in our library10.1016/j.ejca.2014.07.014

56. 56.
    L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile · 2018

    No notice
57. 57.

    Talhouk A, McConechy MK, Leung S, et al. Confirmation of promise: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 2017;123:802–13.

    Not in our library10.1002/cncr.30496

58. 58.

    Wortman BG, Bosse T, Nout RA, et al. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial. Gynecol Oncol 2018;151:69–75.

    Not in our library10.1016/j.ygyno.2018.07.020

59. 59.

    Bosse T, Nout RA, McAlpine JN, et al. Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. Am J Surg Pathol 2018;42:1–8.

    Not in our library10.1097/pas.0000000000001020

60. 60.

    Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007;19:309–14.

    Not in our library10.1016/j.coi.2007.04.012

61. 61.

    Post CCB, Westermann AM, Bosse T, et al. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Crit Rev Oncol Hematol 2020;152:102973.

    Not in our library10.1016/j.critrevonc.2020.102973

62. 62.

    Lee V, Murphy A, Le DT, et al. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist 2016;21:1200–11.

    Not in our library10.1634/theoncologist.2016-0046

63. 63.

    Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1–10.

    Not in our library10.1200/jco.19.02105

64. 64.

    Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 2019;37:2786–94.

    Not in our library10.1200/jco.19.01021

65. 65.

    Antill YC, Kok PS, Robledo K, et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601). J Clin Oncol 2019;37:5501–01.

    Not in our library10.1200/jco.2019.37.15_suppl.5501

66. 66.

    Lim JSJ, Tan DSP. Understanding resistance mechanisms and expanding the therapeutic utility of PARP inhibitors. Cancers 2017;9.. [Epub ahead of print: 22 Aug 2017].

    Not in our library10.3390/cancers9080109

67. 67.

    Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 2012;18:5856–64.

    Not in our library10.1158/1078-0432.ccr-12-0662

68. 68.

    Barra F, Evangelisti G, Ferro Desideri L, et al. Investigational PI3K/Akt/mTOR inhibitors in development for endometrial cancer. Expert Opin Investig Drugs 2019;28:131–42.

    Not in our library10.1080/13543784.2018.1558202

69. 69.

    Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2015;33:930–6.

    Not in our library10.1200/jco.2014.58.3401

70. 70.

    Soliman PT, Westin SN, Iglesias DA, et al. Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: a multi-center, single arm, phase II study. Clin Cancer Res 2020;26:581–7.

    Not in our library10.1158/1078-0432.ccr-19-0471

71. 71.

    Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007;357:39–51.

    Not in our library10.1056/nejmra043186

72. 72.

    Menderes G, Lopez S, Han C, et al. Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it. Discov Med 2018;26:39–50.

    Not in our library

73. 73.

    Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol 2018;36:2044–51.

    Not in our library10.1200/jco.2017.76.5966

74. 74.

    Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20:711–8.

    Not in our library10.1016/s1470-2045(19)30020-8

75. 75.

    Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 2017;23:3711–20.

    Not in our library10.1158/1078-0432.ccr-16-3215

76. 76.

    Galluzzi L, Maiuri MC, Vitale I, et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ 2007;14:1237–43.

    Not in our library10.1038/sj.cdd.4402148

77. 77.

    Samstein RM, Riaz N. The DNA damage response in immunotherapy and radiation. Adv Radiat Oncol 2018;3:527–33.

    Not in our library10.1016/j.adro.2018.08.017

78. 78.

    Derer A, Deloch L, Rubner Y, et al. Radio-immunotherapy-induced immunogenic cancer cells as basis for induction of systemic anti-tumor immune responses - pre-clinical evidence and ongoing clinical applications. Front Immunol 2015;6:505.

    Not in our library10.3389/fimmu.2015.00505

Cited by papers we hold 2

• The role of IGF2BP3/SPOP/c-Myc loop in paclitaxel resistance of endometrial cancer · 2025
  Not checked
• Cancer of the corpus uteri: 2021 update · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.